éå»1ã¶æéã«Grace Therapeutics, Incã«å¯ŸããŠè©äŸ¡ãåºããã¢ããªã¹ã2åã«åºã¥ãããŒã¿ã
仿ãGRCEã¯2ä»¶ã®ãè²·ããã0ä»¶ã®ãäžç«ïŒããŒã«ãïŒãã0ä»¶ã®ã売ããè©äŸ¡ãç²åŸããŸãããçŽè¿1ã¶æã«ãããGRCEã®ã¢ããªã¹ãå¹³åç®æšæ ªäŸ¡ã¯6.000ã§ãã
ã¢ããªã¹ãäºæ³ã«ãããšãFY2027Q1ã«çºè¡šãããEPS -0.914ã«ç¶ããGRCEã®FY2027Q2ã®EPSã¯-0.150ã«éããèŠéãã§ããçºè¡šãããå®çžŸå€ãšäºæ³ãæ¯èŒããŠãåçæ§ã®æšç§»ã確èªããŸãããã
åžå Žäºæ³ã¯ USD -0.91 ã§ããããGrace Therapeutics, IncGRCE ã®åååæã®äžæ ªåœããå©ç (EPS) 㯠USD -0.07 ã§ãããæ¬¡ã®ååæã® EPS 㯠USD -0.15 ãšäºæ³ãããŸãã